For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Dr. Daniel Meltzer, a weight loss expert, suggests that it's possible to maintain weight loss after using GLP-1 medications by creating proper habits, including exercise and eating well. He emphasizes ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

The following content is for informational purposes only. This article is not intended to be a substitute for profession ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter ... the common barriers that make weight loss so challenging, including the feelings ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Age, diabetes status ... analysed were associated with hyper-response versus non-response. Determining clinical and demographic factors associated with weight loss response to GLP-1 analogues is ...

Glucagon-like peptide 1 ... as weight loss agents—have been linked with behavioral side effects. A large population-based analysis in Diabetes, Obesity and Metabolism assessed whether certain genetic ...